Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpACIN-neo neoadjuvant ipilimumab + nivolumab in stage III melanoma
2016-001984-35Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and nivolumab in cutaneous melanoma (CM) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Safety (immune-related adverse events). Started Apr 2017; status: active.
02
Drugs
ipilimumabnivolumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2016-001984-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001984-35.